# US 2023/0416414 A1 · Apolipoprotein nanodiscs with telodendrimer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0416414 A1
- Document ID: US20230416414A1
- Status: Published application
- Kind: A1
- Application number: 18/334,034
- Filed: 2023-06-13
- Published: 2023-12-28
- Earliest claimed: 2011-12-21
- Assignees: Lawrence Livermore National Security, LLC
- Applicants: Lawrence Livermore National Security, LLC
- Inventors: Juntao LUO; Wei HE; Kit S. LAM; Paul HENDERSON; Matthew A. COLEMAN
- Web page: https://patentgrep.com/patent/US20230416414A1

## CPC

- C07K 17/02: Peptides being immobilised on, or in, an organic carrier
- C07K 14/775: Apolipopeptides
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides a nanodisc with a membrane scaffold protein. The nanodisc includes a membrane scaffold protein, a telodendrimer and a lipid. The membrane scaffold protein can be apolipoprotein. The telodendrimer has the general formula PEG-L-D-(R)n, wherein D is a dendritic polymer; L is a bond or a linker linked to the focal point group of the dendritic polymer; each PEG is a poly(ethylene glycol) polymer; each R is and end group of the dendritic polymer, or and end group with a covalently bound hydrophobic group, hydrophilic group, amphiphilic compound, or drug; and subscript n is an integer from 2 to 20. Cell free methods of making the nanodiscs are also provided.

## Claims

### Claim 1

A nanodisc comprising:
a membrane scaffold protein;
a telodendrimer;
a lipid; and
a hydrophobic drug,
wherein the hydrophobic drug is covalently bound to a dendritic segment of the telodendrimer.

### Claim 2 (depends on 1)

The nanodisc of claim 1, wherein the membrane scaffold protein is apolipoprotein.

### Claim 3 (depends on 1)

The nanodisc of claim 1, wherein the telodendrimer has the formula:
PEG-D-(R)n
wherein
D is a dendritic polymer having a single focal group and a plurality of end groups;
PEG is polyethyleneglycol (PEG) of 1-100 kDa linked to the focal group of the dendritic polymer;
each R is independently selected from the group consisting of the end group of the dendritic polymer and an amphiphilic compound, such that when R is not an end group each R is linked to one of the end groups; and
subscript n is an integer from 2 to 20, wherein subscript n is equal to the number of end groups on the dendritic polymer, and wherein at least half the number n of R's are each an amphiphilic compound.

### Claim 4 (depends on 3)

The nanodisc of claim 3, wherein the dendritic polymer is a poly(lysine) dendritic polymer wherein each end group is hydroxy.

### Claim 5 (depends on 3)

The nanodisc of claim 3, wherein each amphiphilic compound is cholic acid (CA).

### Claim 6 (depends on 5)

The nanodisc of claim 5, wherein the telodendrimer is selected from the group consisting of PEG5k-D-CA8, PEG5k-D-CA4 and PEG2k-D-CA4, wherein each dendritic polymer D is a poly(lysine) dendritic polymer wherein each end group is hydroxy.

### Claim 7 (depends on 1)

The nanodisc of claim 1, wherein the lipid is selected from the group consisting of a phospholipid, cholesterol, a phosphatidylcholine, a phosphatidylethanolamine, a phosphatidylglycerol, a phosphatidylserine, and a phosphatidylinositol.

### Claim 8 (depends on 7)

The nanodisc of claim 7, wherein the lipid is selected from the group consisting of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-ditetradecanoyl-sn-glycero-3-phosphocholine (DMPC), 1-tetradecanoyl-2-hexadecanoyl-sn-glycero-3-phosphocholine (MPPC), 1,2-dioctadecanoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1,2-distearoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DSPG), 1,2-dipalmitoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DPPG), 1-tetradecanoyl-2-hexadecanoyl-sn-glycero-3-phosphoglycerol (MPPG) and cholesterol.

### Claim 9 (depends on 7)

The nanodisc of claim 7, wherein the lipid is DMPC.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The nanodisc of claim 1, wherein the hydrophobic drug is selected from the group consisting of amphotericin B and SN38.

### Claim 12 (depends on 1)

The nanodisc of claim 1, wherein the nanodisc is less than about 100 nm in size.

### Claim 13 (depends on 1)

The nanodisc of claim 1, wherein the nanodisc is less than about 10 nm in size.

### Claim 14 (depends on 1)

The nanodisc of claim 1, wherein the ratio of lipid to telodendrimer is from about 200:1 to about 5:1 (w/w).

### Claim 15 (depends on 1)

The nanodisc of claim 1, wherein the ratio of lipid to telodendrimer is about 9:1 (w/w).

### Claim 16

A cell-free method of snaking a nanodisc, the method comprising:
forming a vesicle comprising a telodendrimer and a lipid, wherein the ratio of lipid to telodendrimer is from about 500:1 to about 1:1 (w/w); and
forming a reaction mixture of the vesicle and a membrane scaffold protein in the absence of a cell, thereby preparing the nanodisc
wherein the telodendrimer comprises a hydrophobic drug covalently bound to a dendritic segment of the telodendrimer.

### Claim 17 (depends on 16)

The method of claim 16, wherein the membrane scaffold protein is apolipoprotein.

### Claim 18 (depends on 16)

The method of claim 16, wherein the reaction mixture further comprises a lysate, a buffer, and a polymerase.

### Claim 19 (depends on 16)

The method of claim 16, wherein the lipid:telodendrimer are present in a ratio of about 99:1 (w/w).

### Claim 20 (depends on 16)

The method of claim 16, wherein the lipid:telodendrimer are present in a ratio of about 9:1 (w/w).
